FDA advisors OK AstraZeneca, Sanofi antibody for infants for RSV
Narisara Nami | Moment | Getty Images A panel of independent advisors to the Food and Drug Administration unanimously recommended Thursday that the antibody nirsevimab be approved for use to protect infants from respiratory syncytial virus, the leading cause of hospitalization among newborns. If the FDA approves nirsevimab, the antibody would become the first medical … Read more